New advances in type 1 diabetes

Savitha Subramanian,Farah Khan,Irl B Hirsch

DOI: https://doi.org/10.1136/bmj-2023-075681

2024-01-26

BMJ

Abstract:ABSTRACT Type 1 diabetes is an autoimmune condition resulting in insulin deficiency and eventual loss of pancreatic β cell function requiring lifelong insulin therapy. Since the discovery of insulin more than 100 years ago, vast advances in treatments have improved care for many people with type 1 diabetes. Ongoing research on the genetics and immunology of type 1 diabetes and on interventions to modify disease course and preserve β cell function have expanded our broad understanding of this condition. Biomarkers of type 1 diabetes are detectable months to years before development of overt disease, and three stages of diabetes are now recognized. The advent of continuous glucose monitoring and the newer automated insulin delivery systems have changed the landscape of type 1 diabetes management and are associated with improved glycated hemoglobin and decreased hypoglycemia. Adjunctive therapies such as sodium glucose cotransporter-1 inhibitors and glucagon-like peptide 1 receptor agonists may find use in management in the future. Despite these rapid advances in the field, people living in under-resourced parts of the world struggle to obtain necessities such as insulin, syringes, and blood glucose monitoring essential for managing this condition. This review covers recent developments in diagnosis and treatment and future directions in the broad field of type 1 diabetes.

medicine, general & internal

What problem does this paper attempt to address?

The main focus of this paper is the latest advances in type 1 diabetes. Type 1 diabetes is an autoimmune disease that results in the destruction of pancreatic β-cells and a lack of insulin, requiring lifelong insulin injections. Despite significant technological advancements such as insulin delivery and blood glucose monitoring, many patients still struggle to achieve optimal blood sugar control. The researchers discuss the latest developments in the epidemiology, diagnostic methods, technological advancements (such as continuous glucose monitoring and automated insulin delivery systems), and immunotherapy for type 1 diabetes. Additionally, the paper mentions the increasing incidence of type 1 diabetes in adults, the role of genetic risk scoring in predicting disease progression, and the potential applications of new treatment approaches such as sodium-glucose cotransporter 2 inhibitors and GLP-1 receptor agonists. Although technology has rapidly advanced, obtaining basic diabetes management tools remains a challenge in resource-limited areas.